| 000 | 01529 a2200481 4500 | ||
|---|---|---|---|
| 005 | 20250515192010.0 | ||
| 264 | 0 | _c20091217 | |
| 008 | 200912s 0 0 eng d | ||
| 022 | _a0946-1965 | ||
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aCastro, N | |
| 245 | 0 | 0 |
_aPopulation pharmacokinetics of albendazole in patients with neurocysticercosis. _h[electronic resource] |
| 260 |
_bInternational journal of clinical pharmacology and therapeutics _cNov 2009 |
||
| 300 |
_a679-85 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAdolescent |
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aAlbendazole _xanalogs & derivatives |
| 650 | 0 | 4 |
_aAnthelmintics _xpharmacokinetics |
| 650 | 0 | 4 | _aBiological Availability |
| 650 | 0 | 4 | _aChromatography, High Pressure Liquid |
| 650 | 0 | 4 |
_aDrug Monitoring _xmethods |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aModels, Biological |
| 650 | 0 | 4 |
_aNeurocysticercosis _xdrug therapy |
| 650 | 0 | 4 | _aNonlinear Dynamics |
| 650 | 0 | 4 | _aProspective Studies |
| 650 | 0 | 4 | _aYoung Adult |
| 700 | 1 | _aMárquez-Caraveo, C | |
| 700 | 1 | _aBrundage, R C | |
| 700 | 1 | _aGonzález-Esquivel, D | |
| 700 | 1 | _aSuárez, A M | |
| 700 | 1 | _aGóngora, F | |
| 700 | 1 | _aJara, A | |
| 700 | 1 | _aUrizar, J | |
| 700 | 1 | _aLanao, J M | |
| 700 | 1 | _aJung, H | |
| 773 | 0 |
_tInternational journal of clinical pharmacology and therapeutics _gvol. 47 _gno. 11 _gp. 679-85 |
|
| 999 |
_c19232367 _d19232367 |
||